The name of Western medicine. Common dosage forms are tablets. Anti-chronic hepatitis C virus (HCV) infection. For the treatment of chronic hepatitis C virus (HCV) infection in adults.
Generic name: Vipataivir
English name: Velpatasvir
Chinese pinyin: Weipatawei
Drug type : Anti-chronic hepatitis C virus infection
Prescription type: Prescription drugs
Type of medical insurance is not medical insurance
ingredient
Sofosbuvir vipataivir tablets: a compound preparation consisting of sofosbuvir and vipataivir.
character
Sofosbuvir vipataivir tablet: Film coated tablet, white to brown-yellow after removal of coating. The film is indented with “GSI” on one side and “7916” on the other.
indication
This product is used to treat chronic hepatitis C virus (HCV) infection in adults.
specification
Sofosbuvir vipataivir tablets: Each tablet contains 400mg sofosbuvir and 100mg vipataivir.
Usage and dosage
The usage and dosage of this product may be different in different dosage forms and specifications, please read the specific drug instructions for use, or follow the doctor’s advice.
Sofosbuvevepataivir tablets:
1. The recommended dose is one tablet orally once a day, with or without food.
2, if a dose is missed within 18 hours of the normal time, the patient should be instructed to take the tablet as soon as possible, after which the patient should take the next dose at the usual time of medication. If more than 18 hours have passed, the patient should be instructed to wait until the usual dose time to take the next dose. Patients should be instructed not to take double doses.
3. For patients who have failed previous treatment with NS5A: 24 weeks of treatment with this product plus ribavirin can be considered (see [Precautions]).
4. Elderly: For elderly patients, dose adjustment is not required (see Pharmacokinetics).
5. Renal function damage: For patients with mild or moderate renal function damage, there is no need to adjust the dose of this product. Safety and efficacy have not been evaluated in patients with severe renal impairment (estimated glomerular filtration rate [eGFR]<30mL/min/1.73m2) or in patients with end-stage renal disease (ESRD) requiring hemodialysis (see Pharmacokinetics).
6. Liver function impairment: For patients with mild, moderate or severe liver function impairment (CPTA, grade B or C), there is no need to adjust the dose of this product (see [Pharmacokinetics]). The safety and efficacy of this product have been evaluated in patients with CPTB-grade cirrhosis, but have not been evaluated in patients with CPTB-grade cirrhosis (see [Precautions], [Adverse reactions], and [Pharmacotoxicology]).
7. Children: The safety and efficacy of Epclusa in children and adolescents under 18 years of age have not been determined. No data is available.
8. Administration method: oral administration. Patients should be instructed to swallow the tablets whole, either with or without food (see Pharmacokinetics). Because of the bitter taste, it is recommended not to chew or crush the film coating tablets.
About Wisdom Drugs
Wisdom Drugs Co .,Ltd was founded in Sep. 2011 whose headquarter located in Changzhou Creative Industry Park, having a branch in India. The company’s R&D center is engaged in not only the process development of APIs, intermediates, poly-peptide compounds and heterocyclic compounds,but also the optimization and production. We are devoted to the synthesis customization and the technology transfer, enabling compounds to be scaled from laboratory to commercial to meet the requirements of different customers.
